IL6 and colorectal carcinoma: Ying et al., in a study focused on CRC stem-like cells, demonstrated that IL-6 or Notch 3 inhibition may be superior to STAT3 inhibition for cancer stem cell-targeting therapies concomitant with anticancer drugs [213].